Why clinicians and investors are watching Mirum Pharmaceuticals after its EASL 2026 update
Find out how Mirum Pharmaceuticals’ EASL 2026 data could reshape rare liver disease treatment and investor sentiment.
SalubrisBio’s JK06 shows early promise, but can 5T4 ADCs move beyond niche excitement?
Find out how SalubrisBio’s JK06 data could reshape 5T4-targeted ADC development in lung and breast cancer.
Could Bayer’s NUBEQA gain a quality-of-life edge after ARACOG cognitive data?
Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026.
Pfizer’s prostate cancer combination delivers strong rPFS signal in TALAPRO-3
Talzenna plus Xtandi improved rPFS in HRR-mutated metastatic prostate cancer. Find out what TALAPRO-3 could change next.
TUNE-401 gives Tune Therapeutics an early signal in the race for finite HBV therapy
Find out how Tune Therapeutics’ TUNE-401 data could reshape the chronic hepatitis B cure race and what risks remain for Phase 2.
Why Immunome’s RINGSIDE data may reset expectations in desmoid tumor treatment
Discover how Immunome’s Phase 3 RINGSIDE data could reshape desmoid tumor treatment and gamma secretase inhibitor competition.
Incyte’s frontMIND data put pressure on decades-old R-CHOP dominance in high-risk DLBCL
Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.
Can Exelixis defend its oncology franchise with deeper CABINET evidence?
Read how Exelixis’ CABINET subgroup data could sharpen cabozantinib’s role in advanced neuroendocrine tumor care.
How Massive Bio’s Reticulum Nexus suite is targeting the hidden bottlenecks in cancer trials
Can Massive Bio’s Reticulum Nexus suite close oncology trial access gaps? Find out how AI agents may reshape cancer trial navigation today!
Can volixibat and brelovitug expand Mirum Pharmaceuticals’ rare liver disease ambitions?
Mirum Pharmaceuticals’ EASL 2026 data deepen its rare liver disease strategy. Find out what changes for PSC, HDV and PFIC care.